Skip to main content

Jeffrey Conn Archives

Findings reveal new target in quest to ease schizophrenia

May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.

Read more


Grant spurs schizophrenia research

Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

Read more


Conn lands Javits Neuroscience Investigator award

Aug. 7, 2014—Vanderbilt University’s P. Jeffrey Conn, Ph.D., has won a Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke for discoveries that could lead to new treatments for anxiety, schizophrenia and other brain disorders.

Read more


Hamm’s lasting impact commended at Flexner Discovery Lecture

Jun. 19, 2014—In their introductions of Heidi Hamm, Ph.D., prior to her Flexner Discovery Lecture last week, Susan Wente, Ph.D., and P. Jeffrey Conn, Ph.D., recounted how early encounters with her influenced their careers. For Wente, associate vice chancellor for Research, senior associate dean of Biomedical Science and soon-to-be University Provost, it was a lecture that Hamm...

Read more


‘Missing link’ may spur new brain disorder drugs

Mar. 13, 2014—Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

Read more


AstraZeneca, VU collaborate to develop new treatments for major brain disorders

Jan. 14, 2013—AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.

Read more


Record number elected AAAS fellows

Nov. 29, 2012—Seventeen members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science (AAAS) this year.

Read more


Nobel in Chemistry reveals VU ties that bind

Oct. 18, 2012—Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners.

Read more


VU, Bristol-Myers to collaborate on Parkinson’s therapies

Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

Read more


Insights for neuroscience drug discovery

Jul. 17, 2012—When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.

Read more


Minds wide open: Neuroscience at Vanderbilt

Apr. 6, 2012—Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience.

Read more


Drug-like molecules aimed at improving treatment of Parkinson’s

Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more